DSS Narrows Losses Amid Revenue Growth, Cash Drain Concerns

Ticker: DSS · Form: 10-Q · Filed: Nov 14, 2025 · CIK: 771999

Sentiment: bearish

Topics: Net Loss, Revenue Growth, Cash Burn, Debt Increase, Biotechnology Merger, Multi-segment Business, Liquidity Risk

Related Tickers: DSS

TL;DR

**DSS is burning cash despite revenue growth, and its massive short-term debt spike makes it a risky bet.**

AI Summary

DSS, Inc. reported a net loss of $10.087 million for the nine months ended September 30, 2025, an improvement from the $15.762 million net loss in the same period of 2024. Total revenue increased by 21.5% to $16.630 million in the first nine months of 2025, up from $13.681 million in 2024, driven primarily by a 15.9% rise in printed products revenue to $13.249 million and a 61% increase in rental revenue to $2.147 million. Operating loss narrowed to $10.384 million from $14.287 million year-over-year. Cash and cash equivalents decreased significantly to $7.019 million as of September 30, 2025, from $11.431 million at December 31, 2024, largely due to $7.576 million used in operating activities and $8.816 million used in financing activities. A notable strategic move includes the pending merger of Impact BioMedical Inc. with Dr Ashleys Limited, awaiting regulatory approval. The company also saw a substantial increase in current portion of long-term debt, net, to $43.146 million from $642,000, indicating significant short-term debt obligations.

Why It Matters

DSS's ability to increase revenue across its diverse segments, particularly in printed products and rental revenue, suggests underlying business strength, but the continued net losses and significant cash burn are critical for investors. The pending Impact BioMedical merger could be a game-changer, potentially unlocking value in the biotechnology sector, but regulatory delays introduce uncertainty. The substantial increase in current long-term debt to $43.146 million from $642,000 raises immediate liquidity concerns, potentially impacting the company's ability to fund operations or future growth initiatives. Competitors in its varied business lines, from packaging to biotech, will be watching how DSS manages its debt and executes its strategic M&A.

Risk Assessment

Risk Level: high — DSS reported a net loss of $10.087 million for the nine months ended September 30, 2025, and used $7.576 million in operating cash flows. The current portion of long-term debt, net, surged from $642,000 at December 31, 2024, to $43.146 million at September 30, 2025, representing a significant short-term financial obligation that could strain liquidity.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate DSS's liquidity position given the substantial increase in current long-term debt and continued net losses. Monitor the progress of the Impact BioMedical merger for potential catalysts, but prioritize understanding how the company plans to address its short-term debt obligations and improve cash flow from operations before considering any investment.

Financial Highlights

debt To Equity
N/A
revenue
$16.630M
operating Margin
N/A
total Assets
$92.123M
total Debt
N/A
net Income
$(10.087M)
eps
N/A
gross Margin
N/A
cash Position
$7.019M
revenue Growth
+21.5%

Revenue Breakdown

SegmentRevenueGrowth
Printed Products$13.249M+15.9%
Rental Revenue$2.147M+61.0%

Key Numbers

Key Players & Entities

FAQ

What were DSS, Inc.'s total revenues for the nine months ended September 30, 2025?

DSS, Inc.'s total revenues for the nine months ended September 30, 2025, were $16.630 million, an increase from $13.681 million in the same period of 2024.

How much was DSS, Inc.'s net loss attributable to common stockholders for the nine months ended September 30, 2025?

The net loss attributable to DSS common stockholders for the nine months ended September 30, 2025, was $9.184 million, an improvement from a loss of $14.034 million in the prior year.

What is the status of the Impact BioMedical Inc. merger mentioned in the DSS 10-Q filing?

The merger between Impact BioMedical Inc. and Dr Ashleys Limited is pending regulatory approval as of November 14, 2025, and the closing date remains uncertain.

How did DSS, Inc.'s cash and cash equivalents change from December 31, 2024, to September 30, 2025?

Cash and cash equivalents for DSS, Inc. decreased from $11.431 million at December 31, 2024, to $7.019 million at September 30, 2025, representing a decline of $4.412 million.

What was the change in DSS, Inc.'s current portion of long-term debt, net, as of September 30, 2025?

The current portion of long-term debt, net, for DSS, Inc. increased significantly to $43.146 million at September 30, 2025, from $642,000 at December 31, 2024.

What are the primary business lines of DSS, Inc.?

DSS, Inc. operates five distinct business lines: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing.

Did DSS, Inc. experience any impairment of intangible assets during the nine months ended September 30, 2025?

Yes, DSS, Inc. recognized an impairment of intangible assets totaling $600,000 for the nine months ended September 30, 2025.

What was the net cash used by DSS, Inc.'s operating activities for the nine months ended September 30, 2025?

DSS, Inc. used $7.576 million in net cash from operating activities for the nine months ended September 30, 2025, compared to $5.889 million used in the same period of 2024.

What is the concentration of credit risk for DSS, Inc. as of September 30, 2025?

As of September 30, 2025, one customer accounted for approximately 25% of DSS, Inc.'s consolidated revenue, and two customers accounted for approximately 36% and 10% of its trade accounts receivable balance.

How many shares of common stock were outstanding for DSS, Inc. as of November 4, 2025?

As of November 4, 2025, there were 9,092,518 shares of DSS, Inc.'s common stock, $0.02 par value, outstanding.

Risk Factors

Industry Context

DSS, Inc. operates in sectors that include printed products and rentals, alongside a strategic focus on biomedical ventures. The printed products market is mature and competitive, often facing pressure from digital alternatives. The rental segment's performance can be cyclical and dependent on economic conditions. The company's diversification into biomedical through mergers suggests an attempt to tap into higher-growth, potentially more volatile markets.

Regulatory Implications

The pending merger of Impact BioMedical Inc. with Dr Ashleys Limited is subject to regulatory approval, which could impact the timeline and success of this strategic initiative. Furthermore, as a publicly traded company, DSS, Inc. must adhere to SEC reporting requirements and other financial regulations, with potential penalties for non-compliance.

What Investors Should Do

  1. Monitor the outcome of the pending merger
  2. Analyze the sustainability of revenue growth
  3. Assess the company's liquidity and debt management strategy
  4. Evaluate the impact of share count increase

Key Dates

Glossary

Accumulated deficit
The cumulative net losses of a company that have not been offset by net income. (DSS, Inc. has an accumulated deficit of $(312.256M) as of September 30, 2025, indicating a history of net losses.)
Assets held for sale
Assets that are classified as held for sale and are available for immediate sale in their present condition and are subject only to terms that are reasonable and customary for the sale of such assets. (The significant decrease in 'Assets held for sale' from $45.158M to $0 indicates a divestiture or reclassification of assets.)
Current portion of long-term debt, net
The portion of a company's long-term debt that is due within the next year. (This line item has dramatically increased from $642,000 to $43.146 million, signaling a significant increase in near-term debt obligations.)
Investment, equity method
An accounting method used to report investments in which the investor has significant influence over the investee but does not have control. (DSS, Inc. holds a small investment valued at $125,000 under this method as of September 30, 2025.)
Right-of-use assets
Assets that represent a lessee's right to use an underlying asset for the lease term. (These assets, related to lease obligations, have decreased slightly from $6.465M to $5.981M.)
Reserve for Credit Losses
An allowance set aside by a company to cover potential losses from uncollectible accounts receivable. (DSS, Inc. has a reserve of $1,014,000 for accounts receivable as of September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, DSS, Inc. has demonstrated revenue growth of 21.5%, reaching $16.630 million, driven by increases in printed products and rental revenue. However, the company continues to operate at a loss, with a net loss of $10.087 million, albeit an improvement from the previous year's $15.762 million. A significant concern is the dramatic increase in the current portion of long-term debt, from $642,000 to $43.146 million, and a substantial decrease in cash and cash equivalents, indicating a tightening liquidity position and increased financial risk.

Filing Stats: 4,404 words · 18 min read · ~15 pages · Grade level 18.6 · Accepted 2025-11-14 15:48:41

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 4

Controls and Procedures

Controls and Procedures 37 PART II OTHER INFORMATION 38 Item 1

Legal Proceedings

Legal Proceedings 38 Item 1A

Risk Factors

Risk Factors 38 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3 Defaults upon Senior Securities 38 Item 4 Mine Safety Disclosures 38 Item 5 Other Information 38 Item 6 Exhibits 38 2 PART I – FINANCIAL INFORMATION ITEM 1 - FINANCIAL STATEMENTS DSS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 7,019,000 $ 11,431,000 Restricted cash 100,000 - Accounts receivable, net 4,139,000 3,068,000 Inventory, net 2,871,000 2,442,000 Marketable securities, current 1,661,000 2,878,000 Assets held for sale - 45,158,000 Current portion of notes receivable, net 199,000 240,000 Current portion of notes receivable - related party 257,000 337,000 Current portion of notes receivable 257,000 337,000 Prepaid expenses and other current assets 858,000 1,141,000 Total current assets 17,104,000 66,695,000 Property, plant and equipment, net 5,004,000 5,381,000 Investment in real estate, net 34,880,000 - Other investments 500,000 500,000 Investment, equity method 125,000 129,000 Marketable securities, noncurrent 8,161,000 6,333,000 Notes receivable, net - 17,000 Notes receivable - related party, net - 112,000 Notes receivable - 112,000 Other assets 1,275,000 162,000 Right-of-use assets 5,981,000 6,465,000 Goodwill 1,769,000 1,769,000 Other intangible assets, net 17,324,000 18,890,000 Total assets $ 92,123,000 $ 106,453,000 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,108,000 $ 2,793,000 Accrued expenses and deferred revenue 2,976,000 2,651,000 Other current liabilities 3,250,000 4,193,000 Current portion of lease liability 602,000 606,000 Current portion of long-term debt, net 43,146,000 642,000 Current portion of long-term debt on assets held-for-sale, net - 53

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing